Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes and phenytoin dosing: 2020 update
Author: Karnes, J.H.
Rettie, A.E.
Somogyi, A.A.
Huddart, R.
Fohner, A.E.
Formea, C.M.
Lee, M.T.M.
Llerena, A.
Whirl-Carrillo, M.
Klein, T.E.
Phillips, E.J.
Mintzer, S.
Gaedigk, A.
Caudle, K.E.
Callaghan, J.T.
Citation: Clinical Pharmacology and Therapeutics, 2021; 109(2):302-309
Publisher: American Society for Clinical Pharmacology and Therapeutics
Issue Date: 2021
ISSN: 0009-9236
Statement of
Jason H. Karnes, Allan E. Rettie, Andrew A. Somogyi, Rachel Huddart, Alison E. Fohner, Christine M. Formea ... et al.
Abstract: Phenytoin is an antiepileptic drug with a narrow therapeutic index and large inter-patient pharmacokinetic variability, partly due to genetic variation in CYP2C9. Furthermore, the variant allele HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotypes (updates on
Keywords: CPIC
Stevens-Johnson syndrome
toxic epidermal necrolysis
Description: First published: 11 August 2020
Rights: © 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics
DOI: 10.1002/cpt.2008
Grant ID:
Appears in Collections:Aurora harvest 4
Pharmacology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.